- Home
- PAVM vs NEUP Comparison
PAVM vs NEUP Comparison
Compare PAVM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- NEUP
- Stock Information
- Founded
- PAVM 2014
- NEUP 1996
- Country
- PAVM United States
- NEUP United States
- Employees
- PAVM N/A
- NEUP N/A
- Industry
- PAVM Medical/Dental Instruments
- NEUP
- Sector
- PAVM Health Care
- NEUP
- Exchange
- PAVM Nasdaq
- NEUP Nasdaq
- Market Cap
- PAVM 8.2M
- NEUP 9.1M
- IPO Year
- PAVM 2016
- NEUP N/A
- Fundamental
- Price
- PAVM $0.61
- NEUP $4.84
- Analyst Decision
- PAVM Strong Buy
- NEUP Strong Buy
- Analyst Count
- PAVM 1
- NEUP 1
- Target Price
- PAVM $19.00
- NEUP $21.00
- AVG Volume (30 Days)
- PAVM 211.5K
- NEUP 77.8K
- Earning Date
- PAVM 03-25-2025
- NEUP 02-14-2025
- Dividend Yield
- PAVM N/A
- NEUP N/A
- EPS Growth
- PAVM N/A
- NEUP N/A
- EPS
- PAVM 0.53
- NEUP N/A
- Revenue
- PAVM $4,034,000.00
- NEUP $662,715.00
- Revenue This Year
- PAVM $52.90
- NEUP N/A
- Revenue Next Year
- PAVM $248.84
- NEUP N/A
- P/E Ratio
- PAVM $1.12
- NEUP N/A
- Revenue Growth
- PAVM 166.27
- NEUP N/A
- 52 Week Low
- PAVM $0.57
- NEUP $2.12
- 52 Week High
- PAVM $2.84
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- PAVM 38.86
- NEUP N/A
- Support Level
- PAVM $0.59
- NEUP N/A
- Resistance Level
- PAVM $0.70
- NEUP N/A
- Average True Range (ATR)
- PAVM 0.06
- NEUP 0.00
- MACD
- PAVM -0.02
- NEUP 0.00
- Stochastic Oscillator
- PAVM 8.61
- NEUP 0.00
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.